20 Advanced Solid Tumors Clinical Trials in Palo Alto, CA (2026)

Q: How do I join a clinical trial in Palo Alto?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Palo Alto research site will contact you.

Recruiting Advanced Solid Tumors Studies in Palo Alto

NCT02693535Recruiting

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or ...

Palo Alto, CAPHASE24,200 participantsAmerican Society of Clinical Oncology

View Study Details

NCT03486873Recruiting

Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this ex...

Palo Alto, CAPHASE33,500 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06179160Recruiting

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies....

Palo Alto, CAPHASE1710 participantsIncyte Corporation

View Study Details

NCT06384807Recruiting

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

This is a Phase 1/2, first in human (FIH), open-label, multicenter study of BHV-1510 monotherapy and in Combination with Cemiplimab in participants with previously treated, advanced solid tumors....

Palo Alto, CAPHASE1500 participantsBiohaven Therapeutics Ltd.

View Study Details

NCT05410145Recruiting

A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and prel...

Palo Alto, CAPHASE1442 participantsD3 Bio (Wuxi) Co., Ltd

View Study Details

NCT05007782Recruiting

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

This is a first-in-human (FIH) study to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of denikitug (also known as GS...

Palo Alto, CAPHASE1416 participantsGilead Sciences

View Study Details

NCT07343024Recruiting

Methods of Identifying Effective Off-Guideline Treatments for Advanced Cancer Patients (CC N-of-1)

Many FDA-approved drugs are not available to patients with a particular cancer because there has been no successful clinical trial conducted for that drug against that cancer. In the absence of such a...

Palo Alto, CA300 participantsCancer Commons

View Study Details

NCT06840886Recruiting

A Study of PHST001 in Advanced Solid Tumors

This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy...

Palo Alto, CAPHASE1272 participantsPheast Therapeutics

View Study Details

NCT05732831Recruiting

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is...

Palo Alto, CAPHASE1225 participantsTango Therapeutics, Inc.

View Study Details

NCT06219941Recruiting

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

The purpose of this study is to assess the safety, tolerability, efficacy, pharmacokinetics (PK), and immunogenicity of AZD0901 as monotherapy and in combination with anti-cancer agents in participant...

Palo Alto, CAPHASE2224 participantsAstraZeneca

View Study Details

NCT04981119Recruiting

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible p...

Palo Alto, CA200 participantsA2 Biotherapeutics Inc.

View Study Details

NCT05270213Recruiting

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

RBS2418 (investigational product) is a specific immune modulator, working through ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1), designed to lead to anti-tumor immunity by increasing endo...

Palo Alto, CAPHASE1164 participantsRiboscience, LLC.

View Study Details

NCT06532565Recruiting

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

The main goal of this first-in-human (FIH) study is to learn about the safety and dosing of GS-2121 when given alone or in combination with zimberelimab (ZIM) in participants with advanced solid tumor...

Palo Alto, CAPHASE1154 participantsGilead Sciences

View Study Details

NCT04142437Recruiting

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with ...

Palo Alto, CA150 participantsBayer

View Study Details

NCT04851119Recruiting

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to tr...

Palo Alto, CAPHASE1147 participantsChildren's Oncology Group

View Study Details

NCT02215928Recruiting

Genomic Profiling in Recommending Treatment for Patients With Metastatic Solid Tumors

This research trial studies using genomic profiling to recommend anticancer treatment to patients with cancer that has spread beyond the original site of the tumor (metastatic cancer). Genomic profili...

Palo Alto, CA100 participantsStanford University

View Study Details

NCT04901702Recruiting

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never...

Palo Alto, CAPHASE190 participantsSt. Jude Children's Research Hospital

View Study Details

NCT05635643Recruiting

Study of CHS-114 in Participants With Advanced Solid Tumors

This is a Phase 1, open-label, first-in-human, dose-escalation and expansion study of CHS-114, a monoclonal antibody that targets CCR8, as a monotherapy in patients with solid tumors....

Palo Alto, CAPHASE187 participantsCoherus Oncology, Inc.

View Study Details

NCT05329103Recruiting

A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced sol...

Palo Alto, CAPHASE165 participantsPeel Therapeutics Inc

View Study Details

NCT07356453Recruiting

A Study of PARG Inhibitor FORX-428 in Patients With Advanced Solid Tumors.

The goal of this interventional study is to evaluate the safety and tolerability of escalating doses of FORX-48 as monotherapy in patients with select advanced solid tumors with BRCA1/2 mutations or o...

Palo Alto, CAPHASE140 participantsFoRx Therapeutics AG

View Study Details

About Advanced Solid Tumors Clinical Trials in Palo Alto

Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.

There are currently 20 advanced solid tumors clinical trials recruiting participants in Palo Alto, CA. These studies are seeking a combined 11,986 participants. Research is being sponsored by American Society of Clinical Oncology, Merck Sharp & Dohme LLC, Incyte Corporation and 16 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Advanced Solid Tumors Clinical Trials in Palo Alto — FAQ

Are there advanced solid tumors clinical trials in Palo Alto?

Yes, there are 20 advanced solid tumors clinical trials currently recruiting in Palo Alto, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Palo Alto?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Palo Alto research site will contact you about next steps.

Are clinical trials in Palo Alto free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Palo Alto studies also compensate for your time and travel.

What advanced solid tumors treatments are being tested?

The 20 active trials in Palo Alto are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.

Data updated July 20, 2026 from ClinicalTrials.gov